RxDoctor Payments DataLook up a doctor →

Kumar Abhishek, MD

Internal Medicine · Mechanicsville, VANPI 1083827018

Payments from drug & device makers

$1,045,306in general payments, 2019–2025

Across 1,525 payments — averaging $685.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$348K
  • Daiichi Sankyo Inc.$175K
  • Amgen$62K
  • Medtronic$44K
  • Jazz Pharmaceuticals Inc.$43K
  • Novartis$43K
  • plus $330K from 54 others

What the payments were for

  • Consulting fees$153,96715%
  • Speaking & faculty fees$743,53871%
  • Grants$3500%
  • Travel & lodging$110,25511%
  • Food & beverage$32,8493%
  • Education$3530%
  • Other$3,0330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)294$347,960
Daiichi Sankyo Inc.211$174,923
Amgen77$62,387
Medtronic(2 entities)53$43,836
Jazz Pharmaceuticals Inc.37$42,936
Novartis123$42,675
GSK25$41,646
Genentech USA, Inc.65$39,999
Ipsen Biopharmaceuticals, Inc40$36,539
Sanofi43$28,084
Puma Biotechnology, Inc.24$20,237
Incyte Corporation34$19,530
Bayer38$18,880
Astellas Pharma US Inc25$17,284
Stryker3$16,031
Karyopharm Therapeutics Inc.16$15,620
E.r. Squibb & Sons, L.L.C.44$13,554
EMD Serono, Inc.14$11,064
Eisai Inc.29$9,669
Lilly USA, LLC16$6,748
Rigel Pharmaceuticals, Inc.8$5,186
Verastem, Inc.4$3,993
Stemline Therapeutics Inc.2$3,509
Regeneron Healthcare Solutions, Inc.8$2,719
Pfizer37$2,248
Takeda Pharmaceuticals U.S.A., Inc.5$2,173
Astellas Pharma Global Development1$1,992
EUSA Pharma (US) LLC4$1,846
Exelixis Inc.5$1,541
Merck36$1,453
Janssen Scientific Affairs, LLC1$1,010
Astrazeneca UK Limited1$1,005
Life Spine, Inc.1$784
Sanofi-aventis U.S. LLC3$669
Johnson & Johnson(2 entities)25$473
Intuitive Surgical1$443
Cepheid1$425
Zimmer Biomet2$387
Seagen Inc.19$361
Cardinal Health 110 LLC1$275
Gilead(2 entities)9$199
Pharmacyclics LLC, An Abbvie Company11$187
AbbVie(2 entities)10$185
Bard Peripheral Vascular, Inc.4$182
Tersera Therapeutics LLC7$174
Bristol Myers Squibb10$173
Taiho Oncology, Inc.7$170
Foundation Medicine, Inc.7$157
Array Biopharma Inc8$139
Agios Pharmaceuticals, Inc.5$94
Adaptive Biotechnologies Corporation4$89
Dova Pharmaceuticals4$87
Novocure Inc.4$86
Boston Scientific3$85
Tactile Systems Technology Inc2$79
Beigene USA, Inc.4$77
Tempus AI, Inc3$75
ADC Therapeutics America, Inc.4$73
Caris MPI, Inc.3$71
Pharmacosmos Therapeutics Inc.2$61

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,045,306 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$189,442
Medicare patients
558
Services billed
1,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate67$1,088,023
CabometyxCabozantinib S-Malate23$593,744
RevlimidLenalidomide26$455,593
IbrancePalbociclib27$432,526
Lenalidomide22$358,407
Kisqali Femara Co-PackRibociclib Succinate/Letrozole18$347,082
TagrissoOsimertinib Mesylate14$238,955
JakafiRuxolitinib Phosphate13$217,318
VenclextaVenetoclax15$188,918
EliquisApixaban58$37,359
XareltoRivaroxaban15$20,788
Abiraterone Acetate15$20,714
Letrozole409$9,057
Dexamethasone63$1,947
Prochlorperazine Maleate53$1,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$42,675$1,088,02367 claims
Exelixis Inc.Cabometyx$1,541$593,74423 claims
PfizerIbrance, Eliquis$2,248$469,88585 claims
Bristol Myers SquibbRevlimid$173$455,59326 claims
AstraZenecaTagrisso$347,960$238,95514 claims
Incyte CorporationJakafi$19,530$217,31813 claims
AbbVieVenclexta$185$188,91815 claims
Johnson & JohnsonXarelto$473$20,78815 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$1,010$20,71415 claims
Lilly USA, LLCOlanzapine$6,748$36923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →